Swiss biotechstartup ALP Bio has secured €161,000 (CHF 150,000) from Venture Kick to supportthe commercial development of its platform, which helps drug developersidentify immune-related risks earlier...

Source: Tech.eu — read the full report at the original publisher.

This is a curated wire item. The Continuum Brief does not republish full third-party articles; this entry links to the original source.